New evidence shows high-potency marijuana use dramatically increases the risk of severe psychiatric disorders, with young people and frequent users most vulnerable.
At a Glance
- THC levels in cannabis products have risen fivefold since the early 2000s.
- A 2025 Canadian study found heavy cannabis users up to 14 times more likely to develop schizophrenia-spectrum disorders.
- Neuroimaging research links cannabis use disorder to dopamine abnormalities tied to psychosis.
- Adolescents and those with a family history of mental illness face the highest risks.
- Regulators allowed rising potency with limited oversight despite mounting evidence.
Surge in Potency, Surge in Risk
The marijuana consumed today is significantly stronger than in past decades. Potency, measured by THC concentration, has risen more than fivefold since the early 2000s, meaning users are now exposed to far greater psychoactive effects. Research led by Dr. Daniel Myran at the University of Ottawa in 2025 provided strong evidence that heavy users of high-THC cannabis were much more likely to be diagnosed with schizophrenia-spectrum disorders. Population-level data quantified this risk, reporting up to a 14-fold increase among frequent users.
Watch now: Marijuana and Psychosis Explained · YouTube
Neuroimaging studies reinforce these findings, linking cannabis use disorder with disruptions in dopamine activity. These abnormalities are directly associated with psychosis symptoms such as paranoia and hallucinations. The convergence of epidemiological, clinical, and neurological data strengthens the argument that today’s cannabis is a major contributor to rising rates of psychiatric illness.
Who Is Most at Risk?
While cannabis use carries risks across all demographics, certain groups face disproportionately severe outcomes. Longitudinal research published in PubMed Central in 2025 confirmed that regular use during adolescence substantially increases the likelihood of psychosis, with young males especially vulnerable. For families, this risk translates into increased emergency room visits, psychiatric hospitalizations, and long-term care burdens.
Another danger lies in self-medication. Many young people turn to marijuana for relief from anxiety or depression, but studies now show this may accelerate the onset of severe psychiatric illness. Evidence indicates that while stopping cannabis use can reduce the risk over time, damage may persist, particularly among those who began using heavily at a young age.
The broader social costs are mounting. Rising cases of cannabis-induced psychosis strain already overburdened mental health systems. Emergency rooms, psychiatric clinics, and public health budgets increasingly reflect the fallout of legalization policies that underestimated or ignored these risks.
Industry Pushback and Policy Gaps
Despite the accumulating evidence, cannabis industry advocates often point to older or inconclusive studies to argue that risks are exaggerated. Regulators, under pressure from industry lobbying and revenue incentives, have permitted increasingly potent products with limited safeguards. Studies in Psychological Medicine and reports from Schulich Medicine & Dentistry highlight the growing scientific consensus, yet policy adjustments remain slow.
Conservative critics argue that these developments confirm longstanding concerns about the consequences of legalization. They emphasize the need to re-center drug policy around family stability, mental health protection, and community safety. Public health experts are now calling for stricter regulations, stronger education campaigns, and evidence-based policies that account for the psychiatric risks associated with modern cannabis.
Sources
ScienceDaily
Schulich Medicine & Dentistry
Psychiatrist.com
PMC
Psychiatry & Psychotherapy Podcast
